Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference210 articles.
1. Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM);Ahn;Journal of Clinical Oncology,2016
2. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial;Ahn;Journal of Thoracic Oncology,2016
3. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors;Akbay;Cancer Discovery,2013
4. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment;Alexandrova;Nature,2015
5. EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics;Arcila;Molecular Cancer Therapeutics,2013
Cited by 109 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy;European Journal of Medicinal Chemistry;2024-10
2. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24
3. Custom-Designed Probes for the Accurate Determination of Epidermal Growth Factor Receptor Mutations and Their Allelic Configuration;Analytical Chemistry;2024-06-04
4. Investigating EMT-mediated resistance to EGFR tyrosine kinase inhibitors in NSCLC using innovative organoid models;2024-02-12
5. Addition of bevacizumab to EGFR tyrosine kinase inhibitors in advanced NSCLC: an updated systematic review and meta-analysis;Frontiers in Pharmacology;2024-01-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3